Phase IIa trial in Duchenne Muscular Dystrophy shows vamorolone is a firs-in- class dissociative steroidal anti-inflammatory drug.

LS Conklin, JM Damsker, EP Hoffman, WJ Jusko, PD Mavroudis, BD Schwartz, LJ Mengle-Gaw, EC Smith, JK Mah, M Guglieri, Y Nego, N Kuntz, CM McDonald, T Mar, MM Ryan, R Webster, D Castro, RS Finkel, AL Smith, LP MorgenrothArrieta Aa, M Shimony, M Jaros, P Shale, JM MdDall, Hathout, K Magaraju, den Anker J van, LM Ward, A Ahmet, HR Cornish, PR Clemens

Research output: Contribution to journalArticle

Original languageEnglish (US)
JournalPharmacologic Research
Volume36
StatePublished - 2018

Cite this

Conklin, LS., Damsker, JM., Hoffman, EP., Jusko, WJ., Mavroudis, PD., Schwartz, BD., Mengle-Gaw, LJ., Smith, EC., Mah, JK., Guglieri, M., Nego, Y., Kuntz, N., McDonald, CM., Mar, T., Ryan, MM., Webster, R., Castro, D., Finkel, RS., Smith, AL., ... Clemens, PR. (2018). Phase IIa trial in Duchenne Muscular Dystrophy shows vamorolone is a firs-in- class dissociative steroidal anti-inflammatory drug. Pharmacologic Research, 36.